Durhalieve™

Echo’s lead transdermal product candidate is Durhalieve, an AzoneTS reformulation of triamcinolone acetonide, a widely-used, medium potency corticosteroid approved by the FDA for treatment of corticosteroid-responsive dermatoses. Echo has filed a New Drug Application (NDA) with the FDA seeking market approval for Durhalieve for treatment of corticosteroid-responsive dermatoses. Echo is now in discussions with the FDA regarding the clinical and manufacturing requirements remaining to secure FDA approval of Durhalieve.